Effectiveness of canakinumab treatment in Schnitzler's syndrome: a multi-center randomized placebo-controlled study

Karoline Krause(Humboldt-Universität zu Berlin), Marcus Maurer(Humboldt-Universität zu Berlin), Jörg Fischer(Universitätsklinikum Tübingen), Martin Metz(Humboldt-Universität zu Berlin), Nicola Wagner(Friedrich-Alexander-Universität Erlangen-Nürnberg), Karsten Weller(Humboldt-Universität zu Berlin), Athanasios Tsianakas(University Hospital Münster)
Pediatric Rheumatology
September 28, 2015
10.1186/1546-0096-13-s1-o66
Cited by 6

Related Papers

The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.5k
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
|Allergy|2021|1.2k
The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
|Allergy|2014|1.2k
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
|New England Journal of Medicine|2013|1.1k
The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
|Dermatology Review|2015|429